| Revenue growth | 32% YoY growth; US up 43%, India up 13.9%. |
|---|---|
| Margins | EBITDA margins at 30%; full-year guidance steady at 25%. |
| Demand visibility | Strong chronic segment demand in India; US volume growth healthy. |
| Management confidence | Confident but cautious, flagging near-term competitive headwinds in the US. |
Growth
Revenue grew 32% YoY; US business rose 43% and India 13.9%. Gross margins improved to 74.6% on better product mix.
Outlook
Guided for high single-digit revenue growth and approximately 25% EBITDA margins for full year FY27.
Risks
Near-term moderation in US performance due to competitive entry in Tolevapton and Mirabegron; Geopolitical uncertainty impacts.
Last quarter's promises, checked
Delivered
- Guided 27-28% EBITDA margin → delivered 29.7% (= BEAT)
- Guided high single-digit revenue growth → delivered 23% (= BEAT)
- Targeted chronic segment share 66% → delivered 66% (= BEAT)
Partly delivered
- Guided ETR 22.1% → delivered 30% in Q1 FY27 (= MISS)
Earnings Call Transcript filed with BSE, NSE: LUPIN. Summary written with AI assistance from the document.
Lupin Ltd: key numbers
- Share price
- ₹2,092.00
- Market cap
- ₹95,665 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.3×Sector 50.4×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Employee Stock Options
Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.
Lupin Product Launch
Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.
Lupin Investor Presentation: Key Takeaways
Lupin delivered strong Q1 FY27 results with 33% YoY revenue growth and healthy 30% EBITDA margins, driven by outperformance in US and India markets.
Lupin Q1 FY27 Results: Net Profit ₹1,415 Cr, Up 16.1% YoY
Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,415 Cr (+16.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1,415 Cr · +16.1% YoY
Lupin Q1 FY27 Results: Net Profit ₹1,417 Cr, Up 16.0% YoY
Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,417 Cr (+16.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1,417 Cr · +16.0% YoY
Lupin Earnings Call: Key Takeaways
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.